Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability and Food Effect of JNJ-64417184 in Healthy Subjects
NCT03952507Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of JNJ-64417184 in respiratory syncytial virus infection (RSV) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Relative Bioavailability of JNJ-64417184 at Day 15. Started May 2019; status: completed.
02
Drugs
JNJ-64417184
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03952507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03952507.